Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial

Table 6 Distribution of comorbidity among the study groups

Comorbidity, n (%)	Group A, n (%): Male 46 (75.4), female 15 (24.59)					Group B n (%): Male 33 (71.7), female 13 (28.3)
	Total 61 (58.7)	Recovered cases 21 (34.42)		Death cases 15 (24.59)		Total 46 (44.2)	Recovered cases 24 (52.1)		Death cases 10 (21.7)
		≥ 2 (12)	< 2 (9)	≥ 2 (12)	< 2 (3)		≥ 2 (10)	< 2 (14)	≥ 2 (8)	< 2 (2)
HTN, 22 (19)	16 (15.8)	6 (50)	5 (55.5)	5 (50)	0	22 (21.1)	8 (44.4)	6 (42.8)	7 (87.5)	1 (50)
IHD, 11 (5.5)	8 (7.9)	3 (25)	0	4 (33.3)	1 (33.3)	3 (2.8)	1 (10)	2 (14.2)	0	0
Diabetes mellitus, 28 (14)	15 (14.5)	6 (50)	1 (11.1)	8 (66.6)	0	13 (12.5)	5 (27.8)	1 (7.1)	6 (75)	1 (50)
COPD	5 (4.8)	1 (8.3)	1 (11.1)	3 (25)	0	4 (3.9)	3 (30)	1 (7.1)	0	0
BPH	9 (8.9)	5 (41.6)	0	2 (16.6)	2 (66.6)	3 (2.8)	1 (10)	0	2 (25)	0
Rheumatoid arthritis	4 (3.8)	4 (33.3)	0	0	0	2 (1.9)	1 (10)	1 (7.1)	0	0
Osteoarthritis	5 (4.8)	1 (8.3)	3 (33.3)	0	1 (33.3)	1 (0.9)	0	1 (7.1)	0	0
Hypothyroid	3 (2.9)	2 (16.6)	1 (11.1)	0	0	1 (0.9)	0	1 (7.1)	0	0
Ischemic stroke	2 (1.9)	1 (8.3)	1 (11.1)	0	0	1 (0.9)	0	1 (7.1)	0	0
Heart failure	2 (1.9)	1 (8.3)	0	1 (8.3)	0	2 (1.9)	0	0	2	0
Chronic kidney disease	1 (1)	0	0	0	1 (33.3)	1 (0.9)	0	1 (7.1)	0	0
Bronchial asthma	1 (1)	1 (8.3)	0	0	0	2 (1.9)	0	0	2 (25)	0
IBD	1 (1)	0	0	0	1 (33.3)	0 (0)	0	0	0	0
IBS	0	0	0	0	0	1 (0.9)	0	1 (7.1)	0	0
Hepatitis B	1 (1)	0	1 (8.3)	0	0	1 (0.9)	0	1 (7.1)	0	0
Migraine	1 (1)	1 (8.3)	0	0	0	3 (2.8)	0	1 (7.1)	2 (25)	0
Carcinoma (early)	1 (1)	1 (8.3)	0	0	0	0	0	0	0	0

HTN: hypertension; IHD: Ischemic heart disease; COPD: Chronic obstructive pulmonary disease; BPH: Benign prostatic hyperplasia; IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome.